Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Sales and Divestitures (2021 - 2025)

Journey Medical's Gains from Sales and Divestitures history spans 5 years, with the latest figure at $944946.0 for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 10.72% year-over-year to $944946.0, compared with a TTM value of $944946.0 through Dec 2025, down 10.72%, and an annual FY2025 reading of $944946.0, down 10.72% over the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $944946.0 at Journey Medical, up from $927446.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.1 million in Q4 2024, with the low at $2000.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 5 years is $427501.5, with a median of $293707.0 recorded in 2022.
  • Year-over-year, Gains from Sales and Divestitures skyrocketed 3333.1% in 2023 and then crashed 76.11% in 2025.
  • Tracing DERM's Gains from Sales and Divestitures over 5 years: stood at $136500.0 in 2021, then soared by 115.17% to $293707.0 in 2022, then surged by 147.61% to $727249.0 in 2023, then soared by 45.53% to $1.1 million in 2024, then dropped by 10.72% to $944946.0 in 2025.
  • Per Business Quant, the three most recent readings for DERM's Gains from Sales and Divestitures are $944946.0 (Q4 2025), $927446.0 (Q3 2025), and $324159.0 (Q2 2025).